Emerging Company Profile

Primmune: tolerable TLR7 agonists for systemic immune responses

Emerging Company Profile: San Diego-based Primmune is developing oral host-directed antivirals that activate TLR7 signaling

Primmune is developing oral TLR7 agonists to treat viral infections and cancer via systemic activation of innate immunity without inflammation.

Primmune is designing oral TLR7 agonists that induce antiviral responses without systemically inducing pro-inflammatory genes.

Primmune Therapeutics Inc. President, Chairman and